Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies.

ABSTRACT:

Background

Previous clinical efficacy trials failed to support the continued development of recombinant gp120 (rgp120) as a candidate HIV vaccine. However, the recent RV144 HIV vaccine trial in Thailand showed that a prime/boost immunization strategy involving priming with canarypox vCP1521 followed by boosting with rgp120 could provide significant, although modest, protection from HIV infection. Based on these results, there is renewed interest in the development of rgp120 based antigens for follow up vaccine trials, where this immunization approach can be applied to other cohorts at high risk for HIV infection. Of particular interest are cohorts in Africa, India, and China that are infected with clade C viruses.

Methodology/principal findings

A panel of 10 clade C rgp120 e

SUBMITTER: Smith DH 

PROVIDER: S-EPMC2920315 | biostudies-literature | 2010 Aug

REPOSITORIES: biostudies-literature